Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1

* overall healthy subjects * non-childbearing potential females included

* history of significant sensitivity to any drug * positive test for HAV IgM, HBsAg, anti-HCV Ab or anti-HIV Ab * history of gastrointestinal issues or procedures * history of seizures, diabetes or cancer (except basal cell carcinoma) * clinically significant cardiovascular, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder * use of tobacco or nicotine-containing products with the 6-month period prior to study drug administration * donation or loss of 550 mL or more blood volume or receipt of a transfusion of any blood product within 8 weeks prior to study drug administration * abnormal screening laboratory results that are considered clinically significant by the investigator * current enrollment in another clinical study * previous enrollment in this study * recent (6-month) history of drug/alcohol abuse that could preclude adherence to the protocol * pregnant or breastfeeding female * requirement for any OTC and/or prescription medication, vitamins and/or herbal supplements on a regular basis